Home › Addition Of Amgen Drug Boosts Benefits In Relapsed Myeloma: Study
 

Keywords :   


Addition Of Amgen Drug Boosts Benefits In Relapsed Myeloma: Study

2014-12-08 09:04:12| Biotech - Topix.net

Significantly more patients with relapsed multiple myeloma responded to a three-drug regimen including Amgen Inc's Kyprolis than those who got the standard two-drug treatment, according to results from a late-stage trial. Patients with the blood cancer who received the Kyprolis regimen for 18 months also had a longer duration of response and reported better health-related quality of life, data presented on Saturday showed.

Tags: addition study benefits drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Atlantic Tropical Weather Outlook
05.07Eastern North Pacific Tropical Weather Outlook
04.07Hurricane Beryl Graphics
04.07Hurricane Beryl Forecast Discussion Number 25
04.07Hurricane Beryl Public Advisory Number 25
04.07Summary for Hurricane Beryl (AT2/AL022024)
04.07Hurricane Beryl Wind Speed Probabilities Number 25
04.07Hurricane Beryl Forecast Advisory Number 25
More »